CRX 675

Drug Profile

CRX 675

Alternative Names: CRX-675

Latest Information Update: 25 May 2007

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Antiallergics
  • Mechanism of Action Toll-like receptor 4 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Seasonal allergic rhinitis

Most Recent Events

  • 05 Jul 2005 Data from a media release have been added to the adverse events and Asthma therapeutic trials sections
  • 26 Apr 2004 Phase-I clinical trials in Seasonal allergic rhinitis in USA (Intranasal)
  • 31 Dec 2003 Preclinical trials in Seasonal allergic rhinitis in USA (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top